These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38950582)

  • 1. The Risk of Medication-Related Osteonecrosis of the Jaw in Children: Guidance for Antiresorptive Use in Pediatric Patients.
    Lasky S; Moshal T; Shakoori P; Roohani I; Jolibois M; Youn S; Urata MM; Hammoudeh JA
    J Oral Maxillofac Surg; 2024 Oct; 82(10):1285-1294. PubMed ID: 38950582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
    Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
    J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
    Zhang C; Shen G; Li H; Xin Y; Shi M; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J
    Spec Care Dentist; 2024; 44(2):530-541. PubMed ID: 37219080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E; Bamias A
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
    Liu FC; Luk KC; Chen YC
    Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
    J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
    Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.
    Schiodt M; Vadhan-Raj S; Chambers MS; Nicolatou-Galitis O; Politis C; Coropciuc R; Fedele S; Jandial D; Zhang J; Ma H; Saunders DP
    Support Care Cancer; 2018 Jun; 26(6):1905-1915. PubMed ID: 29275525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
    Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
    Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
    Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
    Neal TW; Schlieve T
    J Oral Maxillofac Surg; 2022 Oct; 80(10):1686-1690. PubMed ID: 35931181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review.
    Querrer R; Ferrare N; Melo N; Stefani CM; Dos Reis PED; Mesquita CRM; Borges GA; Leite AF; Figueiredo PT
    Support Care Cancer; 2021 Jun; 29(6):2811-2820. PubMed ID: 33140246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
    Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
    Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab.
    Yarom N; Lazarovici TS; Whitefield S; Weissman T; Wasserzug O; Yahalom R
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jan; 125(1):27-30. PubMed ID: 29102242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?
    Colella A; Yu E; Sambrook P; Hughes T; Goss A
    J Oral Maxillofac Surg; 2023 Feb; 81(2):232-237. PubMed ID: 36442534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.